Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma

Phase 1 Study of Clinical Nutrition That Research Safty and Efficacy in Lung Neoplasms And Breast Carcinoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02603016

Enrollment

480

Registered

2015-11-11

Start date

2015-11-30

Completion date

2017-02-28

Last updated

2017-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms, Lung Neoplasms

Keywords

Clinical Nutrition

Brief summary

This study evaluates the efficacy of clinical nutrition to treat lung neoplasms and breast carcinoma.We estimate there will be 480 patients accepted.120 patients will receive GLSE compound,120 patients will recrive Maitake mushroom extract compound,120 patients will recrive Rinseng compound,and 120 patients will be as blank countrol group.Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma

Detailed description

GLSE compound、Maitake mushroom extract compound and Rinseng compound have different mechanism on enhancing immunity.This clinicaltrial compare them the immune effect in the progress of treating lung neoplasms and breast carcinoma.Within the 42 days,we will abide by the plan to evaluate the immunity enhancement by monitoring mmune effector molecules.

Interventions

DRUGGLSE compound

DRUGMaitake mushroom extract compound

DRUGGinseng compound

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* lung cancer and breast cancer patients confirmed by surgery pathology; * ECOG physical stamina score of 0\ 3 points; * Expected lifetime \> 3 months; * Need to receive radiation and chemotherapy; * Heart, liver and kidney function and blood picture is normal,WBC≥4×109/L, neutrophil count≥ 2 x 109 / L,platelet count≥100×109/L, hemoglobin≥100 g/L; * To follow-up, good adherence

Exclusion criteria

* Allergic to text drug; * Pregnancy or lactation women; * Suffering from mental illness of not easy to control, * Have serious mental or cognitive dysfunction; * Can not comply with the experimental scheme or can't cooperate with the follow-up; * The patients who are unfavorable to the subject.

Design outcomes

Primary

Measure	Time frame	Description
T-lymphocyte cell subsets	three mouths	T-lymphocyte cell subsets contains CD3+、CD4+、CD8+、CD28-、CD28+、CD4+CD25+、HLADR+、HLADR-,measured these cells concentration level

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026